JP2004510817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004510817A5 JP2004510817A5 JP2002533858A JP2002533858A JP2004510817A5 JP 2004510817 A5 JP2004510817 A5 JP 2004510817A5 JP 2002533858 A JP2002533858 A JP 2002533858A JP 2002533858 A JP2002533858 A JP 2002533858A JP 2004510817 A5 JP2004510817 A5 JP 2004510817A5
- Authority
- JP
- Japan
- Prior art keywords
- pravastatin
- sodium
- composition
- impurities
- substantially pure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001495 Pravastatin Sodium Drugs 0.000 claims 45
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 claims 45
- 229960002965 Pravastatin Drugs 0.000 claims 37
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 37
- 239000000203 mixture Substances 0.000 claims 32
- 239000012535 impurity Substances 0.000 claims 25
- 239000003960 organic solvent Substances 0.000 claims 16
- 239000002253 acid Substances 0.000 claims 14
- 150000003863 ammonium salts Chemical class 0.000 claims 13
- OQARDMYXSOFTLN-PZAWKZKUSA-N [(1S,3S,7S,8S,8aR)-3-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 OQARDMYXSOFTLN-PZAWKZKUSA-N 0.000 claims 12
- 239000002585 base Substances 0.000 claims 9
- 159000000000 sodium salts Chemical class 0.000 claims 9
- 238000000855 fermentation Methods 0.000 claims 8
- 230000004151 fermentation Effects 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- 239000012296 anti-solvent Substances 0.000 claims 6
- 238000000354 decomposition reaction Methods 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- 238000000605 extraction Methods 0.000 claims 5
- 244000005700 microbiome Species 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 4
- 238000002425 crystallisation Methods 0.000 claims 4
- 230000005712 crystallization Effects 0.000 claims 4
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical group CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims 4
- 238000001953 recrystallisation Methods 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FFWSICBKRCICMR-UHFFFAOYSA-N 5-Methyl-2-hexanone Chemical compound CC(C)CCC(C)=O FFWSICBKRCICMR-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating Effects 0.000 claims 2
- 239000003637 basic solution Substances 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 239000001963 growth media Substances 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 230000001376 precipitating Effects 0.000 claims 2
- 238000005185 salting out Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical group ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 claims 1
Claims (71)
a)プラバスタチンの濃縮有機溶液を形成し、
b)そのアンモニウム塩としてプラバスタチンを沈殿し、
c)再結晶化によって当該アンモニウム塩を精製し、
d)当該アンモニウム塩をプラバスタチンナトリウムに置き換え、そして
e)プラバスタチンラクトン及びエピプラバを実質的に含まないプラバスタチンナトリウム単離すること、
を含んで成る方法によって製造される、実質的に純粋なプラバスタチンナトリウム。Next stage:
a) forming a concentrated organic solution of pravastatin;
b) precipitating pravastatin as its ammonium salt;
c) purifying the ammonium salt by recrystallization,
d) replacing the ammonium salt with pravastatin sodium, and e) isolating pravastatin sodium substantially free of pravastatin lactone and epiprava,
Substantially pure pravastatin sodium produced by a process comprising:
発酵液中にプラバスタチンを生成せしめ;そして
プラバスタチン又はそのナトリウム塩を発酵液から、ギ酸C2−C4アルキル又はC2−C4カルボン酸のC1−C4アルキルエステルの少なくとも1種類から本質的に成る溶剤を使用して、プラバスタチン又はそのナトリウム塩を抽出する、ことを含んで成る方法。A method for isolating pravastatin or a sodium salt thereof from a fermentation broth,
During the fermentation liquor yielding pravastatin; and essentially of pravastatin or at least one sodium salt from the fermentation liquor that, C 1 -C 4 alkyl esters of formic acid C 2 -C 4 alkyl or C 2 -C 4 carboxylic acid Extracting pravastatin or a sodium salt thereof using a solvent comprising:
当該組成物は、前記プラバスタチンナトリウムに対して、0.1%以下のエピプラバを含んで成り、そして
当該組成物は、
微生物により生産されたプラバスタチンを含有する発酵液から有機溶剤を用いてプラバスタチンを抽出し、ここで前記抽出工程において、式:CH3CO2R(式中、Rは3〜4個の炭素を有するアルキル基である)を有する有機溶剤を使用し;
酸を用いて不純物を減少せしめ;
塩基を用いて不純物を減少せしめ;そして
結晶化せしめる;
工程の組合わせにより得られうる、
ことを特徴とする組成物。A composition comprising pravastatin sodium comprising:
The composition comprises no more than 0.1% epiprava relative to the pravastatin sodium, and the composition comprises:
Pravastatin is extracted from a fermentation broth containing pravastatin produced by microorganisms using an organic solvent, and in the extraction step, the formula: CH 3 CO 2 R (wherein R has 3 to 4 carbons) Using an organic solvent having an alkyl group);
Reduce impurities with acid;
Use a base to reduce impurities; and crystallize;
Can be obtained by a combination of processes,
The composition characterized by the above-mentioned.
a)プラバスタチンの濃縮有機溶液を形成し、
b)そのアンモニウム塩としてプラバスタチンを沈殿し、
c)再結晶化によって当該アンモニウム塩を精製し、
d)当該アンモニウム塩をプラバスタチンナトリウムに置き換え、そして
e)プラバスタチンラクトン及びエピプラバを実質的に含まないプラバスタチンナトリウム単離すること、
を含んで成る方法によって製造される、実質的に純粋なプラバスタチンナトリウムを含んで成る組成物。Next stage:
a) forming a concentrated organic solution of pravastatin;
b) precipitating pravastatin as its ammonium salt;
c) purifying the ammonium salt by recrystallization,
d) replacing the ammonium salt with pravastatin sodium, and e) isolating pravastatin sodium substantially free of pravastatin lactone and epiprava,
A composition comprising substantially pure pravastatin sodium produced by a process comprising:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23827800P | 2000-10-05 | 2000-10-05 | |
PCT/US2001/031230 WO2002030415A1 (en) | 2000-10-05 | 2001-10-05 | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004278522A Division JP2005013238A (en) | 2000-10-05 | 2004-09-24 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2005237299A Division JP2006036781A (en) | 2000-10-05 | 2005-08-18 | Process for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004510817A JP2004510817A (en) | 2004-04-08 |
JP2004510817A5 true JP2004510817A5 (en) | 2005-10-20 |
JP3737801B2 JP3737801B2 (en) | 2006-01-25 |
Family
ID=22897222
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002533858A Expired - Fee Related JP3737801B2 (en) | 2000-10-05 | 2001-10-05 | Pravastatin sodium substantially free of pravastatin lactone and epipravastatin, and a composition comprising the same |
JP2004278522A Withdrawn JP2005013238A (en) | 2000-10-05 | 2004-09-24 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2005237299A Pending JP2006036781A (en) | 2000-10-05 | 2005-08-18 | Process for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2009191951A Withdrawn JP2009268479A (en) | 2000-10-05 | 2009-08-21 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2013011711A Withdrawn JP2013128486A (en) | 2000-10-05 | 2013-01-25 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2015152088A Pending JP2015212300A (en) | 2000-10-05 | 2015-07-31 | Process for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004278522A Withdrawn JP2005013238A (en) | 2000-10-05 | 2004-09-24 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2005237299A Pending JP2006036781A (en) | 2000-10-05 | 2005-08-18 | Process for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2009191951A Withdrawn JP2009268479A (en) | 2000-10-05 | 2009-08-21 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2013011711A Withdrawn JP2013128486A (en) | 2000-10-05 | 2013-01-25 | Method for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
JP2015152088A Pending JP2015212300A (en) | 2000-10-05 | 2015-07-31 | Process for producing pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1330245A4 (en) |
JP (6) | JP3737801B2 (en) |
KR (1) | KR20030059173A (en) |
CN (1) | CN1468098A (en) |
AU (1) | AU2002211462A1 (en) |
CA (1) | CA2422744A1 (en) |
CZ (1) | CZ20031166A3 (en) |
HR (1) | HRP20030347A2 (en) |
HU (1) | HUP0400913A2 (en) |
IL (1) | IL155194A0 (en) |
IS (1) | IS6766A (en) |
MX (1) | MXPA03002963A (en) |
NO (1) | NO20031532D0 (en) |
NZ (1) | NZ525631A (en) |
PL (1) | PL361230A1 (en) |
SK (1) | SK5232003A3 (en) |
WO (1) | WO2002030415A1 (en) |
ZA (1) | ZA200302313B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1265604T1 (en) * | 1999-11-30 | 2007-04-30 | Sag Teva Gyogyszergyar Zartkoe | Process for recovering statin compounds from a fermentation broth |
CN1754872A (en) * | 1999-11-30 | 2006-04-05 | 特瓦药厂有限公司 | Process for recovering statin compounds from a fermentation broth |
EP1798214A3 (en) * | 1999-11-30 | 2007-08-01 | Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság | Process for recovering statin compounds from a fermentation broth |
CZ20021998A3 (en) | 1999-12-14 | 2003-02-12 | Biogal Gyogyszergyar Rt. | Novel forms of pravastatin sodium salt |
NZ525631A (en) * | 2000-10-05 | 2005-05-27 | Biogal Gyogyszergyar | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
JP3236282B1 (en) * | 2000-10-16 | 2001-12-10 | 三共株式会社 | How to purify pravastatin |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
EP1452519A1 (en) * | 2003-02-25 | 2004-09-01 | Balkanpharma-Razgrad AD | Method for the isolation and purification of pravastatin sodium |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
UY28501A1 (en) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | CHEMICAL COMPOUNDS |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
JP2007512366A (en) | 2003-11-24 | 2007-05-17 | テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ | Method for purifying pravastatin |
NZ552389A (en) | 2004-08-06 | 2009-05-31 | Transform Pharmaceuticals Inc | Statin pharmaceutical compositions and related methods of treatment |
ES2254028B1 (en) * | 2004-11-29 | 2007-03-01 | Ercros Industrial, S.A. | PROCEDURE FOR OBTAINING PRAVASTATIN SODIUM PURIFIED. |
KR20070099034A (en) * | 2005-02-25 | 2007-10-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | Process of purifying tadalafil |
JP4813841B2 (en) * | 2005-07-25 | 2011-11-09 | キユーピー株式会社 | Method for producing pravastatin sodium |
HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
CN114031496A (en) * | 2021-11-30 | 2022-02-11 | 广东蓝宝制药有限公司 | Preparation method of high-purity pravastatin 1,1,3, 3-tetramethylbutylamine |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3378441A (en) * | 1963-10-17 | 1968-04-16 | S B Penick & Company | Tetraene antibiotic purification |
JPS5221594B2 (en) * | 1973-09-29 | 1977-06-11 | ||
DK141099B (en) * | 1975-02-07 | 1980-01-14 | Glaxo Lab Ltd | Process for purifying clavulanic acid or a salt thereof with a base. |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (en) * | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
JPS572240A (en) * | 1980-06-06 | 1982-01-07 | Sankyo Co Ltd | Ml-236b derivative |
JPS5889191A (en) * | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | Preparation of 3-hydroxy-ml-236b derivative |
JPS5890509A (en) * | 1981-11-25 | 1983-05-30 | Sankyo Co Ltd | Composition for remedy of hypercholesterolemia |
JPH01190661A (en) * | 1988-01-22 | 1989-07-31 | Konishi Kagaku Kogyo Kk | Purification of 4,4'-dihydroxydiphenylsulfone |
JP2739328B2 (en) * | 1988-09-14 | 1998-04-15 | 日本ケミファ株式会社 | Purification method of benzimidazole compound |
US5202029A (en) * | 1991-03-13 | 1993-04-13 | Caron Kabushiki Kaisha | Process for purification of hmg-coa reductase inhibitors |
NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
JPH06256278A (en) * | 1993-03-03 | 1994-09-13 | Nissan Chem Ind Ltd | Optically active alpha-carbamoylalkanoic acid derivative and its production |
CA2126365C (en) * | 1993-07-06 | 1999-08-24 | Steven W. Felman | Recovery of citric acid from impure process streams by addition of strong acids and salts thereof |
AU677890B2 (en) * | 1994-03-31 | 1997-05-08 | Danisco Cultor America, Inc. | Process for natamycin recovery |
DK0784605T3 (en) * | 1995-08-03 | 2000-07-31 | Dsm Nv | Selective procedure for the deacylation of acyl compounds |
JPH09124655A (en) * | 1995-11-01 | 1997-05-13 | Sankyo Co Ltd | New squalene synthase inhibition-active compound |
EP0877089A1 (en) * | 1997-05-07 | 1998-11-11 | Gist-Brocades B.V. | HMG-CoA reductase inhibitor preparation process |
SI20070A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE |
SI20072A (en) * | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | PROCEDURE OF PREPARATION OF INHIBITORS OF HMG-CoA REDUCTASE |
JP2000229855A (en) * | 1998-12-07 | 2000-08-22 | Satoshi Takebe | Pravastatin sodium tablet |
MXPA01007807A (en) * | 1999-02-03 | 2003-06-04 | Inst Drug Res Ltd | Microbial process for preparing pravastatin. |
HUP9902352A1 (en) * | 1999-07-12 | 2000-09-28 | Gyógyszerkutató Intézet Kft. | Process for producing pravastatin by microbiological way |
CN1754872A (en) * | 1999-11-30 | 2006-04-05 | 特瓦药厂有限公司 | Process for recovering statin compounds from a fermentation broth |
NZ525631A (en) * | 2000-10-05 | 2005-05-27 | Biogal Gyogyszergyar | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
-
2001
- 2001-10-05 NZ NZ525631A patent/NZ525631A/en unknown
- 2001-10-05 PL PL01361230A patent/PL361230A1/en unknown
- 2001-10-05 CN CNA018168604A patent/CN1468098A/en active Pending
- 2001-10-05 CZ CZ20031166A patent/CZ20031166A3/en unknown
- 2001-10-05 EP EP01979511A patent/EP1330245A4/en not_active Withdrawn
- 2001-10-05 KR KR10-2003-7004764A patent/KR20030059173A/en not_active IP Right Cessation
- 2001-10-05 JP JP2002533858A patent/JP3737801B2/en not_active Expired - Fee Related
- 2001-10-05 CA CA002422744A patent/CA2422744A1/en not_active Abandoned
- 2001-10-05 IL IL15519401A patent/IL155194A0/en unknown
- 2001-10-05 HU HU0400913A patent/HUP0400913A2/en not_active IP Right Cessation
- 2001-10-05 WO PCT/US2001/031230 patent/WO2002030415A1/en not_active Application Discontinuation
- 2001-10-05 MX MXPA03002963A patent/MXPA03002963A/en not_active Application Discontinuation
- 2001-10-05 SK SK523-2003A patent/SK5232003A3/en unknown
- 2001-10-05 AU AU2002211462A patent/AU2002211462A1/en not_active Abandoned
-
2003
- 2003-03-25 ZA ZA200302313A patent/ZA200302313B/en unknown
- 2003-04-01 IS IS6766A patent/IS6766A/en unknown
- 2003-04-04 NO NO20031532A patent/NO20031532D0/en not_active Application Discontinuation
- 2003-05-02 HR HR20030347A patent/HRP20030347A2/en not_active Application Discontinuation
-
2004
- 2004-09-24 JP JP2004278522A patent/JP2005013238A/en not_active Withdrawn
-
2005
- 2005-08-18 JP JP2005237299A patent/JP2006036781A/en active Pending
-
2009
- 2009-08-21 JP JP2009191951A patent/JP2009268479A/en not_active Withdrawn
-
2013
- 2013-01-25 JP JP2013011711A patent/JP2013128486A/en not_active Withdrawn
-
2015
- 2015-07-31 JP JP2015152088A patent/JP2015212300A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004510817A5 (en) | ||
KR100280766B1 (en) | Method for preparing substantially pure enantiomer of phenylpropionic acid | |
JP2003515334A5 (en) | ||
US6833452B2 (en) | Process for the preparation of highly pure crystalline (R,S)—cefuroxime axetil | |
US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
FI101965B (en) | Use of the 2-amino-2,4,4-trimethylpentane salt of clavulanic acid in the preparation of alkali or alkaline earth metal salts of clavulanic acid | |
KR100200242B1 (en) | Process for preparing clavulanic acid salt | |
EP1302467A2 (en) | Process for the preparation of substituted thiazoline derivatives and their intermediate | |
JP2004521875A5 (en) | ||
JP4954421B2 (en) | Purification method of clavulanate | |
KR100537732B1 (en) | Preparation of Clavulanate | |
CA2007385C (en) | Process for the optical resolution of dropropizine | |
US7057066B2 (en) | Process for producing 3-amino-2-hydroxypropionic acid derivatives | |
MXPA01013145A (en) | Method for separating the diastereomer bases of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol. | |
JP2001500114A (en) | Solvent extraction of 3-hydroxymethylcephalosporin | |
JP3883525B2 (en) | Method for purifying pravastatin sodium | |
JP2001521393A (en) | Method for isolating pharmaceutically acceptable alkali metal salts of clavulanic acid | |
JPH0374384A (en) | Optical resolution of 3r-(3-carboxybenzyl)-6- (5-fluoro-2-benzothiazolyl)methoxy-4r-chromanol | |
JP2001526291A (en) | Method for purifying solution of ampicillin prodrug ester | |
JP3316917B2 (en) | New phenylalanine salt crystals and their production | |
JPS6121939B2 (en) | ||
JP2022072636A (en) | Method for producing amide compound | |
CN115594640A (en) | Refining method of dibenzoyl thiamine disulfide | |
JP2000198779A (en) | Purification of 3-alkylflavanol derivative | |
WO2000053609A1 (en) | Process for the preparation of cefuroxime |